NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome

被引:64
作者
Assier, E
Jullien, V
Lefort, J
Moreau, JL
Di Santo, JP
Vargaftig, BB
Silva, JRLE
Thèze, J
机构
[1] Inst Pasteur, Unite Immunogenet Cellulaire, Dept Mol Med, F-75724 Paris, France
[2] Inst Pasteur, Unite Pharmacol Cellulaire, F-75724 Paris, France
[3] Inst Pasteur, Unite Cytokines & Dev Lymphoide, F-75724 Paris, France
[4] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Div Pulm Med, Inst Doencas Torax, Rio De Janeiro, Brazil
关键词
D O I
10.4049/jimmunol.172.12.7661
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanism of IL-2-induced vascular leak syndrome (VLS) is still poorly understood. Cells of both innate and adaptive immune systems have been implicated, but no definitive conclusions have been reached concerning their respective roles. In this study we report a new mouse model of IL-2-induced pulmonary VLS used to obtain a detailed analysis of the early events (sequestration of polymorphonuclear neutrophils and bronchoconstriction) and late events (modifications in the cell and protein content of bronchoalveolar lavages, followed by edema) that characterize this lung injury. This model and knockout animals are used to reconsider the importance of the different leukocyte lineages in early and late events. Recombinase-activating gene 2(-/-) mice are used to demonstrate that adaptive lymphocytes, including NK T cells, are not required for pulmonary VLS induction. By contrast, results obtained with newly described recombinase-activating gene 2(-/-)/IL-15(-/-) mice indicate that NK cells play a key role in both early and late events. In parallel, polymorphonuclear neutrophil depletion is used to evaluate the contributions made by these cells to the late alterations occurring in the lung. Furthermore, when used in combination with inhibition of NO synthase, granulocyte depletion was completely effective in protecting mice from the late events of IL-2-induced pulmonary VLS. Together our results indicate that both NK and PMN cells play a central role in the late events of IL-2-induced VLS.
引用
收藏
页码:7661 / 7668
页数:8
相关论文
共 49 条
  • [1] INDUCTION OF NATURAL-KILLER-CELL MIGRATION BY MONOCYTE CHEMOTACTIC PROTEIN-1, PROTEIN-2 AND PROTEIN-3
    ALLAVENA, P
    BIANCHI, G
    ZHOU, D
    VANDAMME, J
    JILEK, P
    SOZZANI, S
    MANTOVANI, A
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (12) : 3233 - 3236
  • [2] ANDERSON TD, 1993, INT REV EXP PATHOL, V34, P57
  • [3] Vascular leak syndrome: a side effect of immunotherapy
    Baluna, R
    Vitetta, ES
    [J]. IMMUNOPHARMACOLOGY, 1997, 37 (2-3): : 117 - 132
  • [4] Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
    Baluna, R
    Rizo, J
    Gordon, BE
    Ghetie, V
    Vitetta, ES
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) : 3957 - 3962
  • [5] PULMONARY-EDEMA DURING IL-2 THERAPY - COMBINED EFFECT OF INCREASED PERMEABILITY AND HYDROSTATIC-PRESSURE
    BERTHIAUME, Y
    BOITEAU, P
    FICK, G
    KLOIBER, R
    SINCLAIR, GD
    FONG, C
    POON, MC
    LAFRENIERE, R
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (01) : 329 - 335
  • [6] COTRAN RS, 1988, J IMMUNOL, V140, P1883
  • [7] DAMLE NK, 1987, J IMMUNOL, V138, P1779
  • [8] DAMLE NK, 1989, J IMMUNOL, V142, P2660
  • [9] Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment
    David, D
    Naït-Ighil, L
    Dupont, B
    Maral, J
    Gachot, B
    Thèze, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (05) : 730 - 735
  • [10] The first α helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor β chain, and induces lymphokine-activated killer cells
    Eckenberg, R
    Rose, T
    Moreau, JL
    Weil, R
    Gesbert, F
    Dubois, S
    Tello, D
    Bossus, M
    Gras, H
    Tartar, A
    Bertoglio, J
    Chouaïb, S
    Goldberg, M
    Jacques, Y
    Alzari, PM
    Thèze, J
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (03) : 529 - 539